Objective: To study the occurrence of endometriosis or adenomyosis in mothers and sisters of patients with endometriosis.
Methods: A total of 563 patients with endometriosis were interviewed about endometriosis or adenomyosis in their mothers or sisters. Five hundred and twenty-eight patients (94%) gave information about their relatives. Six patients were adopted and had no knowledge about their relatives. Among 522 patients were seven pairs of sisters, of which only one was included, giving a total of 515 cases. The control group consisted of 149 women without endometriosis documented at a recently diagnostic laparoscopy performed in connection with sterilization. The controls were likewise interviewed about their relatives, and none refused to give information. If a gynecological operation in a relative was reported, medical records were obtained (68%) or a description of the medical history was given by the proband.
Results: Endometriosis or adenomyosis was disclosed in 3.9% of mothers of cases and in 0.7% of mothers of controls, in 4.8% of sisters of cases and in 0.6% of sisters of controls. The relative risk of endometriosis in a first-degree relative (expressed as odds ratio), was 7.2 (95% confidence interval 2.1, 24.3). Severe manifestations of endometriosis were found more often among patients with a positive family history than among those without (26% versus 12%, p < 0.01).
Conclusion: The study demonstrates a seven fold increased risk of endometriosis in mothers and sisters of patients with endometriosis. It is assumed that daughters of patients with endometriosis have a similar risk of developing endometriosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/00016349309058164 | DOI Listing |
Expert Opin Drug Saf
January 2025
Department of Obstetrics, The Affiliated Hospital of Qingdao University, Qingdao, China.
Objectives: Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.
Methods: This study performed a retrospective analysis using real-world data extracted from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.
Ultrasound Obstet Gynecol
January 2025
Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.
Objective: Although artificial intelligence (AI) is increasingly being applied to ultrasound imaging in gynecology, efforts to synthesize the available evidence have been inadequate. The aim of this systematic review was to summarize and evaluate the literature on the role of AI applied to ultrasound imaging in benign gynecological disorders.
Methods: Web of Science, PubMed and Scopus databases were searched from inception until August 2024.
Med J Aust
January 2025
Australian Women and Girls' Health Research Centre, the University of Queensland, Brisbane, QLD.
Objectives: To estimate the prevalence of heavy menstrual bleeding among Australian women from young adulthood to midlife (22-48 years) and investigate the characteristics of women who experience this condition; to investigate the relationship of heavy menstrual bleeding and health-related quality of life.
Study Design: Longitudinal cohort survey study (Australian Longitudinal Study on Women's Health, ALSWH).
Setting, Participants: Australia; baseline cohort of 14 247 women born during 1973-1978, recruited in 1996; eight post-baseline surveys undertaken at 3-year intervals, 2000-2021.
Pharmacol Res Perspect
February 2025
Sumitomo Pharma Switzerland GmbH, Basel, Switzerland.
Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the treatment of endometriosis and uterine fibroids. The aim of this postmarketing study was to determine the pharmacokinetics and quantify the amount of relugolix excreted into breast milk of healthy lactating women. Following a single, oral dose of 40 mg relugolix, breast milk was sampled over 120 h.
View Article and Find Full Text PDFBJOG
January 2025
Department of Obstetrics and Gynecology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!